ArchivesMagazine - 16 Mar 2017Stick with Stock Spirits Turnaround dividing opinion at Polish vodka business 16 March 2017|Great Ideas|by James Crux Share on Facebook Share on Bluesky Share on X (Twitter) Share by Email < UK Pharma & Biotech Stocks Gold miner eyes profit even at low metal prices > Issue: 16 Mar 2017 - Page 14 | Contents Next: Gold miner eyes profit even at low metal prices Previous: UK Pharma & Biotech Stocks Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. Share on Facebook Share on Bluesky Share on X (Twitter) Share by Email James Crux Issue Contents Editor's View Searching for ideas with stock screens Feature Esure escapes Ogden damage 76%: Percentage of money going into European tech firms by US and Asian investors 25%: Ramsdens on the rise 500 tonnes: Morrisons is in good shape AIM Stocks Ranking UK Pharma & Biotech Stocks 3-month low: Oil slips as US activity ramps up 7.9%: Investment trust’s big bet on Sports Direct Should you accept or reject a takeover bid? Power up: dividend reinvestment special How to find the right shares if you want to reinvest dividends There is plenty of life left in Dignity Valuation anomaly puts spotlight on Metal Tiger Portmeirion is unbreakable Quadrise is out of fuel Mountfield is looking healthier Another oil firm plans juicy dividends Funds Funds in turnaround mode Great Ideas PZ Cussons has heritage and growth potential Three reasons why you need shares in Cineworld Stick with Stock Spirits Burford Capital reveals surge in earnings Investment Trusts Investment trusts that pay more and more dividends every year News Where next for Bovis after marriage proposals? Who should you buy in oil services after Amec merger? Segro hopes for Heathrow boost Sturgeon fires starting gun on Scots independence push Gold miner eyes profit even at low metal prices Personal Finance Dealing with new pension and dividend rules We like zero dividend preference shares Under The Bonnet National Grid is about to give £4bn away Week Ahead When will Kraken awake for EnQuest? Can Kier continue to deliver growth? No respite for Next
